News | May 23, 2024
Merck to acquire life science company Mirus Bio for US$ 600 million
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
Additional data from APPRAISE ATP trial reinforce modular therapy approach
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
The award recognizes powerful science–industry collaborations for social good
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subscribe To Our Newsletter & Stay Updated
